These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. The Novel ATP-Competitive MEK/Aurora Kinase Inhibitor BI-847325 Overcomes Acquired BRAF Inhibitor Resistance through Suppression of Mcl-1 and MEK Expression. Phadke MS; Sini P; Smalley KS Mol Cancer Ther; 2015 Jun; 14(6):1354-64. PubMed ID: 25873592 [TBL] [Abstract][Full Text] [Related]
11. Inhibition of BCL2 Family Members Increases the Efficacy of Copper Chelation in BRAF Kim YJ; Tsang T; Anderson GR; Posimo JM; Brady DC Cancer Res; 2020 Apr; 80(7):1387-1400. PubMed ID: 32005716 [TBL] [Abstract][Full Text] [Related]
12. Microenvironment-derived factors driving metastatic plasticity in melanoma. Kim IS; Heilmann S; Kansler ER; Zhang Y; Zimmer M; Ratnakumar K; Bowman RL; Simon-Vermot T; Fennell M; Garippa R; Lu L; Lee W; Hollmann T; Xavier JB; White RM Nat Commun; 2017 Feb; 8():14343. PubMed ID: 28181494 [TBL] [Abstract][Full Text] [Related]
13. The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma. Ramsdale R; Jorissen RN; Li FZ; Al-Obaidi S; Ward T; Sheppard KE; Bukczynska PE; Young RJ; Boyle SE; Shackleton M; Bollag G; Long GV; Tulchinsky E; Rizos H; Pearson RB; McArthur GA; Dhillon AS; Ferrao PT Sci Signal; 2015 Aug; 8(390):ra82. PubMed ID: 26286024 [TBL] [Abstract][Full Text] [Related]
14. Whole-transcriptomic Profile of SK-MEL-3 Melanoma Cells Treated with the Histone Deacetylase Inhibitor: Trichostatin A. Mazzio EA; Soliman KFA Cancer Genomics Proteomics; 2018; 15(5):349-364. PubMed ID: 30194076 [TBL] [Abstract][Full Text] [Related]
15. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib. Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428 [TBL] [Abstract][Full Text] [Related]
17. CRISPR Screens Identify Essential Cell Growth Mediators in BRAF Inhibitor-resistant Melanoma. Li Z; Wang B; Gu S; Jiang P; Sahu A; Chen CH; Han T; Shi S; Wang X; Traugh N; Liu H; Liu Y; Wu Q; Brown M; Xiao T; Boland GM; Shirley Liu X Genomics Proteomics Bioinformatics; 2020 Feb; 18(1):26-40. PubMed ID: 32413516 [TBL] [Abstract][Full Text] [Related]
18. Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade. Penna I; Molla A; Grazia G; Cleris L; Nicolini G; Perrone F; Picciani B; Del Vecchio M; de Braud F; Mortarini R; Anichini A Oncotarget; 2016 Jan; 7(4):3947-65. PubMed ID: 26678033 [TBL] [Abstract][Full Text] [Related]
19. Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction. Moriceau G; Hugo W; Hong A; Shi H; Kong X; Yu CC; Koya RC; Samatar AA; Khanlou N; Braun J; Ruchalski K; Seifert H; Larkin J; Dahlman KB; Johnson DB; Algazi A; Sosman JA; Ribas A; Lo RS Cancer Cell; 2015 Feb; 27(2):240-56. PubMed ID: 25600339 [TBL] [Abstract][Full Text] [Related]